Lawrence Eichenfield, MD

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

Panelists discuss the unique challenges of managing atopic dermatitis in children compared with adults, focusing on factors such as skin barrier differences, treatment adherence, and the impact on growth and development.

Panelists discuss the mental and physical burden of atopic dermatitis on pediatric patients and their caregivers and share approaches to addressing the psychosocial impact of the condition, highlighting how these factors influence treatment selection and care strategies.

Panelists discuss how atopic dermatitis is linked to other type 2 inflammatory conditions in the pediatric population, exploring the shared immune pathways and comorbidities that connect these disorders.

Panelists discuss the pathophysiology of atopic dermatitis, highlighting the role of type 2 inflammation in driving the disease process and explaining how this inflammation contributes to the characteristic itch-scratch cycle seen in affected individuals.

Larry Eichenfield, MD, discusses how fostering transparent communication with families affected by pediatric vitiligo involves addressing their concerns, setting realistic treatment expectations, providing emotional support, and empowering parents to be advocates for their children’s physical and emotional well-being.

Larry Eichenfield, MD, discusses how pediatric vitiligo can profoundly impact a child’s mental health, self-esteem, and social relationships, requiring a comprehensive care approach that includes psychological support, family counseling, and strategies to help children navigate peer interactions and build resilience.

Larry Eichenfield, MD, discusses how vitiligo manifests uniquely in children through its earlier onset patterns, rapid progression phases, specialized diagnostic challenges for developing skin, and modified treatment approaches that must carefully balance effectiveness with safety concerns for young patients.

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.

Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

In the final part of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 3 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 2 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 1 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

Dr Lawrence F. Eichenfield provides his insight into treating acne as a chronic condition and the importance of personalizing a treatment regimen.

Lawrence F. Eichenfield, MD, shares his perspectives on the management of acne vulgaris highlighting key topics that were covered in a panel discussion held at Maui Derm 2023.

In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.